Abstract: The present invention provides a method for determining a survival rate and prognosis state and providing care for a patient having esophageal carcinoma, comprising: (a) providing a tissue sample from the patient; (b) measuring an expression level of a plurality of target genes comprising peptidase inhibitor 3 (PI3) and CD14 in the tissue sample from the patient using reagents specific for a gene product of the plurality of target genes that are selected from the group consisting of probes, primers, antibodies, and antibody fragments, wherein the expression level is measured by RNA expression or protein expression; (c) comparing the expression level of the plurality of target genes to a predetermined threshold indicative of a survival rate and prognosis state for the patient; and (d) providing care for the patient when the survival rate and prognosis state is worse, wherein the care is advising the patent to reduce the time between return visit or to add adjuvant chemotherapy after surgery.

Abstract: The present invention provides a method for determining a survival rate and prognosis state for a patient having esophageal carcinoma, comprising: (a) providing a tissue sample from the patient; (b) measuring a expression level of a target gene in the tissue sample from the patient using reagents specific for the target gene product that are selected from the group consisting of probes, primers, antibodies, and antibody fragments, wherein the expression level is RNA expression, a protein expression at a cellular level or a tissue level; (c) comparing the expression level to a predetermined threshold indicative of a survival rate and prognosis state for the patient; and (d) providing a survival rate and prognosis state for the patient so that care for the patient is able to be determined in accordance with the survival rate and prognosis state, wherein the target gene is peptidase inhibitor 3 (PI3).

Abstract: The present invention provides a method for predicting the survival rate and prognosis of esophageal carcinoma patients, which is characterized in examining the expression level of a specific gene, peptidase inhibitor 3 (PI3) or CD14 antigen (CD14) in a sample, and comparing to the average expression level of said specific gene from patients to determine the survival and prognosis status for esophageal cancer. The present invention further provides a kit for predicting the survival rate and prognosis of esophageal carcinoma patients.

Abstract: An automated microarray processing system includes a microarray housing assembly module, an incubation module, a washing module and at least one automated transport module. With the automated transport module being mechanically moved among the microarray housing assembly module, the incubation module and the washing module, biochemical reaction of a reaction region of a microarray and a biological sample solution disposed therebetween is automatically performed, and the reacted microarray is automatically cleaned when the biochemical reaction of the microarray is completed.

Abstract: An automated microarray processing system includes a microarray housing assembly module, an incubation module, a washing module and at least one automated transport module. With the automated transport module being mechanically moved among the microarray housing assembly module, the incubation module and the washing module, biochemical reaction of a reaction region of a microarray and a biological sample solution disposed therebetween is automatically performed, and the reacted microarray is automatically cleaned when the biochemical reaction of the microarray is completed.

Abstract: A device and methods are provided for enhancing DNA microarray hybridization speed and discrimination efficiency by means of an electric field.

Abstract: Disclosed are nucleic acid microarray devices and their method of preparation employing dendrimeric polyamines to bind nucleic acid probes to solid support surfaces thereby enhancing the surface molecule density and hybridization efficiency of nucleic acids in the microarray. Also disclosed are methods of using the resulting microarray device for analyzing test samples containing target molecules.